Hyoscine butylbromide

Generic Name: Hyoscine butylbromide

Brand Names: Buscopan

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₃₀NO_₄

CAS Number: 7182-53-8

Unique Ingredient Identifier: 2Z3E1OF81V

Background: Butylscopolamine is a peripherally acting antimuscarinic, anticholinergic agent. It is used to treat pain and discomfort caused by abdominal cramps, menstrual cramps, or other spasmodic activity in the digestive system. It is also effective at preventing bladder spasms. It is not a pain medication in the normal sense, since it does not directly affect pain, but rather works to prevent painful cramps and spasms from occurring. It is on the WHO Model List of Essential Medicines, the most important medications needed in a basic health system.

Indication: Used to treat abdmoninal cramping and pain .

Associated Conditions: Gastrointestinal spastic and hypermotility disorders, Infantile Hypertrophic Pyloric Stenosis, Menstrual Distress (Dysmenorrhea), Muscle Spasms, Pain, Primary Dysmenorrhoea, Stiffness of the Urinary Tract, Acute biliary spasm, Acute gastrointestinal spasms, Acute genitourinary spasms, Genitourinary smooth muscle spasm

Associated Therapies: Analgesia, Smooth muscle relaxation prior to radiological procedures therapy

Clinical Trials

Effect of Hyoscine- Bromide on Duration of the First Stage of Labor

Not Applicable

Recruiting

Conditions: Labor

Interventions: Other: normal saline
Drug: hyoscine butylbromide

First Posted Date: 2023-09-28

Last Posted Date: 2023-10-06

Lead Sponsor: Ain Shams University

Target Recruit Count: 60

Registration Number: NCT06056869

Locations: 🇪🇬
Ain Shams University maternity hospital, Cairo, Cairo/القاهرة, Egypt

SAINT: Safe Induction of Labor Trial

Phase 3

Recruiting

Conditions: Labor Complication
Induced; Birth
Pregnancy Related

Interventions: Drug: Buscopan 20 MG/ML Injectable Solution
Drug: Placebo
Drug: Nacl 0.9%
Drug: Sodium bicarbonate

First Posted Date: 2023-02-09

Last Posted Date: 2024-04-04

Lead Sponsor: Oslo University Hospital

Target Recruit Count: 3000

Registration Number: NCT05719467

Locations: 🇳🇴
Akershus University Hospital, Lørenskog, Norway
🇳🇴
Oslo University Hospital Ullevål, Oslo, Norway
🇳🇴
The University Hospital of North Norway, Tromsø, Norway

and more 2 locations

Efficacy and Safety of CDE100 in the Treatment of Menstrual Cramp Pain Associated With Primary Dysmenorrhea

Phase 3

Not yet recruiting

Conditions: Primary Dysmenorrhea

Interventions: Drug: CDE100 association
Drug: Buscopan® Composto association

First Posted Date: 2022-12-07

Last Posted Date: 2024-02-16

Lead Sponsor: EMS

Target Recruit Count: 238

Registration Number: NCT05640232

Locations: 🇧🇷
Investigational Site, São Paulo, SP, Brazil

Buscopan in Patients Undergoing IVF/Intracytoplasmic Sperm Injection Treatment

Not Applicable

Active, not recruiting

Conditions: IVF
Intracytoplasmic Sperm Injection

Interventions: Drug: Buscopan 20 milligrams/ML Injectable Solution

First Posted Date: 2021-02-11

Last Posted Date: 2024-05-08

Lead Sponsor: Chinese University of Hong Kong

Target Recruit Count: 675

Registration Number: NCT04751084

Locations: 🇭🇰
Prince of Wales Hospital, Hong Kong, Hong Kong

The Effect of Hyoscine-N-butylbromide (HBB, Buscopan) in Augmented Labour Among Primigravidae

Phase 4

Completed

Conditions: Labor Long

Interventions: Other: Placebo
Drug: Hyoscine Butylbromide

First Posted Date: 2020-04-16

Last Posted Date: 2022-04-06

Lead Sponsor: National University of Malaysia

Target Recruit Count: 110

Registration Number: NCT04349722

Locations: 🇲🇾
National University Malaysia Medical Centre, Cheras, Kuala Lumpur, Malaysia

BUSCLAB - Buscopan to Prevent Slow Progress in Labor

Phase 3

Completed

Conditions: Labor; Prolonged, First Stage
Labor (Obstetrics)--Complications

Interventions: Drug: Butylscopolamine Bromide 20 MG/ML
Drug: Sodium Chloride 9mg/mL

First Posted Date: 2019-05-23

Last Posted Date: 2022-12-20

Lead Sponsor: Oslo University Hospital

Target Recruit Count: 250

Registration Number: NCT03961165

Locations: 🇳🇴
Oslo University Hospital Rikshospitalet, Oslo, Norway

Reclassifying Constipation Using Imaging and Manometry

Not Applicable

Conditions: Irritable Bowel Syndrome Characterized by Constipation
Constipation - Functional

Interventions: Procedure: MRI Motility
Procedure: High Resolution Manometry
Drug: Bisacodyl
Drug: Hyoscine butylbromide

First Posted Date: 2017-07-21

Last Posted Date: 2020-07-07

Lead Sponsor: University of Nottingham

Target Recruit Count: 120

Registration Number: NCT03226145

Locations: 🇬🇧
Queen Mary University of London, London, United Kingdom
🇬🇧
University College London, London, United Kingdom
🇬🇧
University of Nottingham, Nottingham, Notts, United Kingdom